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Abstract 
Background: Resistant hypertension is defined as failure to lower blood pressure to 
target when a patient adheres to the maximum tolerated doses of 3 antihypertensive 
drugs including a diuretic. Notwithstanding the wide availability of several 
antihypertensive agents and the continued recommendation of dietary and lifestyle 
modifications, the prevalence of resistant hypertension remains high and is expected 
to increase thus underscoring the need for potential new treatment modalities in 
esistant hypertension. r
 
Objective: Endothelin-1 is a long lasting potent vasoconstrictor and plays a key role 
in cardiovascular haemostasis. Endothelin mediates its biological activity in humans 
through the endothelin A and B receptors. The clinical experience and the evidence 
for therapy with darusentan in resistant systemic hypertension are reviewed. 
 
Methods: The leading journals that publish basic science and clinical research in the 
area of cardiovascular diseases and PubMed were scanned. 
 
Conclusion: While results from early clinical studies suggested that darusentan might 
emerge as new treatment option in patients with resistant hypertension, results from 
recent studies suggests that darusentan appears unlikely to find its way in the 
armamentarium for treatment of resistant hypertension. 
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Introduction 
Worldwide, the estimated number of adults with hypertension was 972 million in 
2000; by 2025 the total number is expected to increase to 1.56 billion[2007, Enseleit 
et al., 2008]. Lifestyle factors, such as alcohol and tobacco use, physical inactivity, a 
salt-rich diet with processed and fatty foods, build the bottom of this disease burden, 
which is spreading at an alarming rate from developing countries to emerging 
economies, such as India and China. In developed countries hypertension remained 
a problematic disorder, despite a functioning health-care system and several 
effective treatment options. Refractory (or resistant) hypertension is defined as blood 
pressure that is persistently higher than the goal, i. e. 130/80 mmHg in patients with 
diabetes mellitus or renal disease, despite prescription of three different classes of 
drugs, including a diuretic in adequate doses[Mancia et al., 2007]. Currently available 
antihypertensive agents are diuretics, aldosterone-receptor blockers, beta-blockers, 
alpha-blockers, combined alpha- and beta-blockers, angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin II receptor blockers (ARBs), the renin-inhibitor aliskiren, 
calcium channel antagonists, central alpha agonists, and direct vasodilators. 
Currently, there are no accepted standards of care for the treatment of patients with 
resistant hypertension and more information is needed to determine the optimal 
evaluation of such patients. The evaluation includes screening for secondary causes 
of resistant hypertension including hyperaldosteronism, improving adherence to 
treatment and identification of exogenous, blood pressure elevating substances. 
Once, the usual initial management steps have failed, the remaining option include 
new agents like endothelin – antagonists. 
 
Yanagisawa reported the isolation, purification, and characterization of ET-1 from the 
culture supernatant of bovine aortic endothelial cells in 1988[Yanagisawa et al., 
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1988]. The early observation that ET-1 is a long lasting and 5 times more potent 
vasoconstrictor compared to angiotensin II, quickly established its importance as a 
major regulator of blood pressure[Yanagisawa et al., 1988, Kiowski et al., 1991]. This 
was the most striking effect of endothelin described at the time of its isolation, and its 
discovery was rapidly followed by the recognition that ET-1 has a major role in the 
pathogenesis of a variety of cardiovascular diseases. Hence, four structurally similar 
isopeptides (ET-1, ET-2, ET-3 and ET-4) exist, ET-1 mediates fundamental cellular 
processes, such as cell proliferation[Janakidevi et al., 1992, Yang et al., 1999], 
fibrosis[Guarda et al., 1993] and inflammation[Ruetten et al., 1997], in human 
cardiovascular physiology[Boulanger et al., 1990] and pathophysiology[Dohi et al., 
1992]. Endothelin mediates its biological activity in humans through the endothelin 
receptors A and B (ET-A, ET-B)[Seo et al., 1994], which are members of the 
heptahelical G-protein-coupled receptor superfamily. The biology of endothelin and 
its receptors is reviewed in detail by Lüscher et al.[Luscher et al., 2000], Motte et 
al.[Motte et al., 2006] and Kirkby et al[Kirkby et al., 2008]. However, the major 
involvement of ET-1 in various pathologic conditions, lead to the development of 
different endothelin receptor antagonists (ERAs) in recent years. The first approved 
ET-antagonist was the dual ET-A/B endothelin receptor antagonist bosentan. Most 
preclinical and clinical studies have been conducted in the field of CHF and 
pulmonary hypertension, more recent research focused on ERAs as treatment option 
in resistant hypertension[Enseleit et al., 2008, Prasad et al., 2009]. 
 
Endothelin receptor antagonism 
Endothelin-1 (ET-1) plays an important role in various physiological and 
pathophysiological states, especially in the regulation of vascular tone. Compared to 
normal state, circulating plasma ET-1 levels are elevated in atherosclerosis, arterial 
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hypertension, heart failure and pulmonary arterial hypertension[Opitz et al., 2008]. 
The two distinct receptor subtypes ET-A and ET-B mediate the downstream effects 
of ET-1. Human ET-A and ET-B bind ET-1 with equal affinity[Kirkby et al., 2008]. 
Endothelin receptor antagonists (ERAs) have been classified as selective for the ET-
A or ET-B receptor or non-selective ET-A / ET-B receptor antagonists. Endothelin 
receptors have been identified in numerous tissues including lung, heart, kidney, 
intestine, adrenal gland, eye and brain, whereas the density of binding sites is 
especially high in heart and lung[Simonson et al., 1990]. In systemic and pulmonary 
vessels, ET-A receptors are located primarily on vascular smooth muscle cells 
(VSMCs)[Maclean et al., 1994], while ET-B receptors are expressed on endothelial 
cells[Ogawa et al., 1991] and VSMCs[Davenport et al., 1993]. While both ET 
receptors mediate vasoconstriction and cell proliferation, endothelial ET-B receptors 
activate the release of vasodilating and anti-proliferative endothelium-derived 
substances, such as prostacyclin or nitric oxide[Motte et al., 2006]. Due to these 
pathophysiological considerations, selective ET-A blockade may be superior over 
combined ET-A/B receptor blockade. However, recent data derived from cultured 
transfected cell lines suggest that ET-A and ET-B receptors can form constitutive 
heterodimers (dimerization theory)[Opitz et al., 2008, Watts, 2010], which means that 
ET-B receptors in heterodimers may mediate vasoconstriction similar to ET-A 
receptors[Gregan et al., 2004, Opitz et al., 2008]. Furthermore, it has been 
hypothesized that a selective blockade of one ET-receptor may result in 
compensation via the unblocked receptor (cross talk)[Opitz et al., 2008]. However, 
whether this translates into clinical benefit in systemic hypertension is still under 
debate, since randomized clinical trials comparing ET-A vs. ET-A/B receptor 
antagonism in heart failure or systemic hypertension are missing. 
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Chemistry 
Knoll AG (Germany) developed darusentan (LU 135252, HMR 4005) was a (+)-(S)-2-
(4,6-Dimethyoxy-pyrimidine-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid and its 
properties were first described in 1995[Raschack et al., 1995]. Chemically, it is a 
slightly water-soluble molecule with a molecular weight of 410 g/mol (Figure 1). 
Darusentan is a selective endothelin-A (ET-A) receptor antagonist, which binds with 
a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to the human ET-B receptor, 
respectively. The drug is orally bioavailable, reaching peak plasma concentrations 1 
hour after oral application and has a mean elimination half life time of 12.5 hours, 
making it suitable for once daily dosing[Cernacek et al., 1998]. Darusentan is 
primarily metabolized in the liver and excreted via the bile, whereas urinary excretion 
is less than 5%[Cernacek et al., 1998]. Darusentan is an experimental drug that is 
not yet on the market. 
 
Studies in Heart Failure 
Three phase II studies in patients with congestive heart failure have been completed 
and published[Spieker et al., 2000, Luscher et al., 2002, Anand et al., 2004]. 
Notwithstanding darusentan improved hemodynamics acutely[Spieker et al., 2000] 
and after three weeks of treatment in chronic heart failure in the HEAT trial[Luscher 
et al., 2002], it did not change LV remodelling over the course of 6 months in 
EARTH[Anand et al., 2004]. While HEAT and EARTH had been powered for 
hemodynamics and LV remodelling, respectively, but not for morbidity or mortality, a 
trend for fluid retention and related events was associated particularly with the 300 
mg dose. 
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Studies in Hypertension 
In view of the potent pressor effects of ET-1, systemic hypertension was early 
recognized as target for ET antagonism[Schrader et al., 1990]. Moreover, circulating 
ET-1 concentration is elevated in patients with essential hypertension[Saito et al., 
1990]. One-kidney one clip (1-K 1C) Goldblatt hypertensive rats exhibit a mild degree 
of vascular overexpression of endothelin-1[Sventek et al., 1996], but combined ET-
A/B antagonism with bosentan did not cause any lowering of blood pressure after two 
weeks treatment[Li et al., 1996]. In another study, darusentan lowered blood 
pressure by 20 mmHg (p<0.01) in DOCA-salt hypertensive rats[Li et al., 1998], 
improved endothelial dysfunction in salt-sensitive Dahl rats[Barton et al., 1998] and 
prevented vascular dysfunction and hypertension induced by 11-hydroxysteroid 
dehydrogenase inhibition[Ruschitzka et al., 2001]. Since combined ET-A/B 
antagonism may block both smooth muscle vasoconstrictor ET-A and ET-B receptors 
and endothelial vasorelaxant ET-B endothelin receptors, the possibility exists that a 
endothelin receptor antagonist which blocks both receptor subtypes may be less 
effective than a selective ET-A endothelin receptor antagonist. This could possibly 
account, for example, for the failure of chronically applied bosentan to lower blood 
pressure in spontaneously hypertensive rats[Schiffrin et al., 1995, Schiffrin et al., 
1995], in contrast to the effect of acute intravenous infusion of an ET-A receptor 
antagonist[Bazil et al., 1992]. Moreover, ET-1 plays a role in atherosclerosis, 
inflammation[Kowala et al., 1995] and diabetes[Schneider et al., 2002]. Hence, 
selective endothelin – antagonism with ET-A selective BQ-123 can reduce blood 
pressure in patients with chronic kidney disease and this effect is synergistic with 
ACE-inhibition[Goddard et al., 2004] and abolished by ET-B blockade. Furthermore, 
ET antagonism may produce favourable renal hemodynamic changes that reduce 
proteinuria in patients with renal disease[Dhaun et al., 2006]. However, the first large 
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clinical trial randomized 293 patients with mild – to – moderate essential 
hypertension to four doses of bosentan, enalapril or placebo[Krum et al., 1998]. After 
4 weeks of treatment, the combined ET-A/B receptor antagonist bosentan (500 mg 
QD) lowered blood systolic and diastolic pressure by 8.4±1.7 mmHg and 5.7±1.0 
mmHg, respectively. This was comparable to enalapril 20 mg QD[Krum et al., 1998]. 
Subsequently, three large clinical trials with the ET-A selective endothelin antagonist 
darusentan in systemic hypertension have been fully reported[Nakov et al., 2002, 
Black et al., 2007, Weber et al., 2009], while the preliminary results of recently 
finished DORADO-AC study have only been reported as press release[2009]. 
The aim of the double – blind, placebo – controlled, randomized HEAT – 2 (HEAT-
HTN) study was to assess the blood pressure lowering effect of three different 
dosages of darusentan versus placebo[Nakov et al., 2002]. After discontinuation of 
antihypertensive medication and a 2-weeks placebo run-in period, patients were 
randomized to 6-weeks treatment with 10 mg, 30 mg or 100 mg darusentan once 
daily or placebo. A subsequent placebo withdrawal period completed the study. 
Office blood pressure was measured at weekly intervals. Between February 1999 
and April 2000 a total of 611 patients were enrolled in 56 centres in Germany and 
Israel. 219 patients discontinued the study during the run – in period, primarily due to 
insufficient blood pressure reduction, adverse event or withdrawal of consent. After 
an initial increase of blood pressure during the placebo run – in phase, blood 
pressure markedly decreased after the first week of therapy. After adjustment for 
baseline blood pressure, study site and after subtraction of placebo mean change, 
systolic and diastolic blood pressure decreased significantly in all active treatment 
groups (Table 1)[Nakov et al., 2002]. Importantly, no effect on heart rate, reflecting 
activation of reflex neurohumoral mechanisms, was observed throughout the study. 
The adverse event profiles of the 10 mg and 30 mg dosage groups were similar to 
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the placebo group, whereas patients in the 100 mg group experienced more adverse 
events, headache, flushing and peripheral oedema in particular. This study 
demonstrated for the first time, that treatment with darusentan in patients with 
moderate hypertension is effective and the blood pressure reduction was dose 
dependent. 
The other phase II study, the DAR-201 trial was a double - blind, randomized, 
placebo – controlled trial in patients with resistant hypertension as defined by the 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood Pressure (JNC 7)[Chobanian et al., 2003]. The study 
was conducted between July 2004 and July 2005 in 30 investigative centres in the 
US[Black et al., 2007]. After completing of a 2-week single – blind placebo run – in 
phase, eligible patients were randomized in a 2:1 fashion to increasing dosages of 
darusentan or placebo. Darusentan was initiated at a dosage of 10 mg/d and titrated 
every 2 weeks at doses of 50, 100 and 150 mg/d until reaching a maximum of 300 
mg/d. One blinded dose maintenance or reduction was allowed, if patients did not 
tolerate up – titration. Importantly, adjustment of background antihypertensive 
therapy was not allowed. A total of 115 patients were randomized (darusentan n = 
76, placebo n = 39)[Black et al., 2007]. 61% of patients had comorbid diabetes 
mellitus, coronary artery disease or both. 93% of the patients were on ACE-I / ARBs, 
67% of patients were on calcium channel blockers, 47% were on beta-blockers and 
all patients were treated with a diuretic. After 10 weeks treatment, up – titration to 
300 mg/d could be performed in 78% of patients. The placebo – corrected systolic 
blood pressure was reduced by 11.5 ± 3.1 mmHg (p = 0.015), while the diastolic 
blood pressure was reduced by 6.3 ± 2.0 mmHg (p=0.002) (Table 2). Ambulatory 
blood pressure measurements revealed a placebo – corrected lowering of systolic 
and diastolic blood pressure by 9.2 ± 2.2 mmHg and 7.2 ± 1.6 mmHg (p < 0.001), 
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respectively[Black et al., 2007]. Heart rate was unaffected by treatment with 
darusentan, compared to baseline (0.4 ± 0.9 bpm and 2.3 ± 1.3 bpm, respectively). 
Reduction in blood pressure was maintained over 24 hours with a trough – to – peak 
ratio of 96%. The most common adverse events in the darusentan group were 
peripheral oedema (17%), followed by headache (11%) and sinusitis (8%). 
 
To date, two Phase III clinical trials in patients with resistant hypertension are 
completed. The DORADO trial (ClinicalTrials.gov Identifier: NCT00330369, Protocol 
DAR-311) screened 718 patients in 117 centers in North and South America, Europe, 
New Zealand, and Australia. 379 patients were enrolled and randomized, however, 
348 patients completed the 14-week treatment period[Weber et al., 2009]. Patients 
were randomized to 50 mg, 100 mg and 300 mg darusentan QD or placebo. The co-
primary endpoints of the study are changes from baseline to week 14 in trough sitting 
systolic and diastolic blood pressure. Importantly, this was a study on top of modern 
therapy for resistant hypertension (≥ three drugs, including a diuretic). All three 
darusentan dosages reduced systolic and diastolic blood pressure significantly 
(p<0.0001), Figure 2[Weber et al., 2009]. While the mean office blood pressure 
(systolic/diastolic) decreased by 18/10 mmHg in the verum group, it decreased by 9/5 
mmHg in the placebo group. Ambulatory blood pressure decreased by 9/8 mmHg in 
the darusentan group and 1/1 mmHg in the placebo group. However, there was no 
evidence for a significant dose response. The blood pressure goal (<140 mmHg or < 
130 mmHg in patients with diabetes or chronic kidney disease) was achieved in 27% 
of patients in the placebo group, 53% in the 50mg group (p=0.0002), 53% in the 
100mg group (p<0.0001) and 48% in the 300mg group (p=0.0007)[Weber et al., 
2009]. Adverse events were mainly related to oedema and / or fluid retention, these 
events occurred in 14% of patients in the placebo group, 25% in the 50mg group, 
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32% in the 100mg group and 25% in the 300mg group. Most of these events 
occurred during the first six weeks of treatment, 2% of the patients had to discontinue 
the study for this reason. However, six patients had serious adverse cardiac events 
during the trial. One sudden death occurred in the placebo group, two patients 
suffered from non-ST segment myocardial infarction (1 in the 50mg group, 1 in the 
100mg group) and were associated with fluid retention and heart failure. In two 
patients in the 300mg group fluid retention and heart failure were noticed and one 
patient in the 100mg group hat atrial fibrillation with symptoms of heart failure[Weber 
et al., 2009]. 
 
In the DORADO-AC study (ClinicalTrials.gov Identifier: NCT00389779, Protocol 
DAR-312) the blood pressure lowering effect of three different doses of darusentan 
(50 mg, 100 mg and 300 mg QD) was compared to 1mg guanfacine QD and placebo. 
Between September 2006 and August 2009, the study enrolled 849 patients with 
resistant hypertension. The co-primary endpoint is the same like in the Protocol DAR-
311. The preliminary results were released to the public in a press release on 
December 14th, 2009[2009]. Gilead Science, the sponsor of the trial reported that 
darusentan failed to achieve the co-primary endpoint (changes from baseline to week 
14 in trough sitting systolic and diastolic blood pressure)[2009]. Although the study 
was 95% powered to detect an 8 mmHg improvement in systolic and diastolic blood 
pressure, reductions in mean trough sitting systolic and diastolic blood pressures 
were not statistically different between darusentan and placebo groups[2009, 
Enseleit et al., 2010]. However, darusentan demonstrated superiority in sitting 
systolic and diastolic blood pressure when compared to the active comparator 
guanfacine after 14 weeks of treatment[Enseleit et al., 2010]. As a result, the 
extension – protocols (DAR-311-E or DAR-AC-E) that were designed to study long-
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term safety and efficacy of darusentan in resistant hypertension in patients that have 
completed the DAR-311 or the DAR-312 protocol, were terminated prematurely. 
 
Safety of darusentan 
Although endothelin receptor antagonists have an acceptable safety profile, side 
effects are relatively common. Indeed, in the HEAT-HTN study 116 (29.6%) of the 
392 patients randomized discontinued the study mainly for lack of treatment effect 
(insufficient blood pressure reduction) or occurrence of adverse events. The most 
frequent reported clinical adverse events of the treatment with darusentan seem to 
be related to non-specific vasodilating effects and include headache, dizziness, 
nausea, peripheral oedema and nasal congestion[Sütsch et al., 1998, Spieker et al., 
2000, Luscher et al., 2002, Packer et al., 2002, Anand et al., 2004]. While the 
incidence of peripheral oedema or fluid retention was observed in up to 27% of the 
darusentan group (vs. 14% in the placebo group) in the trial by Weber et al.[Weber et 
al., 2009], the exact pathophysiological mechanism remains still elusive. Indeed, 
darusentan causes a decrease in blood pressure by a vasoconstrictor blockade, 
leading to peripheral vasodilatation an oedema, as observed with the vasodilatating 
dihydropyridine calcium channel blockers. This is underscored by the finding that 
glomerular filtration rate remained unaffected by treatment[Weber et al., 2009, 
Williams, 2009]. It may be aggravated by dual ERAs due to the reported ET-B 
mediated down-regulation of the epithelial sodium channel in the renal tube[Plato et 
al., 1999]. However, in clinical trials incidence of fluid retention as an adverse event 
has not been reported differently with selective ET-A vs. combined ET-A/B receptor 
antagonists[Motte et al., 2006]. 
Liver toxicity is an often-reported dose – dependent adverse effect during treatment 
with ERAs. This effect appears to be related to impaired bile salt transport, causing 
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accumulation of toxic bile salts in hepatocytes[Fattinger et al., 2001]. The safety 
database of the bosentan trials revealed that liver toxicity occurs early as well as late 
in treatment in 2-18% of patients[Fattinger et al., 2001]. Active surveillance of liver 
function in patients treated with ERAs prevents clinical significant hepatitis but may 
lead to discontinuation of therapy in 5% of treated patients at one year[Motte et al., 
2006]. The “Research on Endothelin Antagonism in Chronic Heart Failure” (REACH-
1) trial[Packer et al., 1998], was terminated prematurely because of a reversible 
increase in concentrations of liver aminotransferases. However, at haemodynamically 
effective doses, darusentan did not show significant elevatation of hepatic enzymes 
in dose-finding studies[Spieker et al., 2000, Luscher et al., 2002]. 
Due to teratogenicity, ERAs are contraindicated during pregnancy and animal models 
revealed that the endothelin system appears to play an important role in fetal 
development[Treinen et al., 1999]. Mice knocked out for the ET-A receptor[Clouthier 
et al., 1998] develop lesions that resemble those seen in the CATCH22 syndrome in 
humans, which include severe craniofacial deformities, defects in the cardiovascular 
outflow tract, thymic hypoplasia and cleft palate[Wilson et al., 1993]. ET-B receptor 
deficient mice develop white spotted coats and aganglionic megacolon, the same 
pathological phenotype as observed in Hirschsprung disease[Hosoda et al., 1994]. In 
CHF, ET – antagonism was associated with a trend towards more adverse events 
(including death) with higher doses, in particular. 
 
Darusentan for the Treatment of Resistant Hypertension 
While human ET-A and ET-B receptors bind ET-1 with equal affinity, endothelin 
receptor antagonists have been classified as selective for the ET-A or ET-B receptor 
or as non-selective, combined ET-A/B receptor antagonists[Kirkby et al., 2008, 
Enseleit et al., 2010]. The ET-A:ET-B binding ratio of the ET-A receptor antagonist 
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BQ-123, of 2000:1 in a standard in vitro assay, is considered the benchmark to 
classify the selectivity of different ETAs[Dupuis, 2000, Goddard et al., 2004]. 
However, darusentan is a borderline selective ET-A receptor antagonist with a 
relative ET-A/B selectivity of 170:1[Neuhofer et al., 2009] and the selectivity for ET-A 
receptors is affected by the dose of the antagonist[Goddard et al., 2002, Dhaun et al., 
2010]. This may explain the very flat or even absent dose-response of darusentan in 
recent trials in patients with resistant hypertension[2009, Weber et al., 2009]. The 
effect of an ETA on plasma ET-1 levels in vivo is considered an indicator of functional 
selectivity. Since ET-B receptors play a role in clearing ET-1, decreasing ET-1 levels 
after treatment with an ET-antagonist suggests selectivity, because ET-B receptors 
remain functional[Opitz et al., 2008]. To further elucidate the ET-receptor selectivity 
of darusentan, plasma levels of ET-1, an established biomarker of ET-receptor 
blockade[Goddard et al., 2004], should be reported. 
Early clinical phase II studies suggested that darusentan might find a place in the 
treatment of resistant hypertension[Enseleit et al., 2008, Enseleit et al., 2010]. 
However, the missing dose-dependency of darusentan in the recently published 
study by Weber et al.[Weber et al., 2009] and the preliminary negative results of the 
DORADO-AC study cast doubt on the concept of ET-antagonism in resistant 
hypertension. Although data regarding the secondary end points and the safety of 
darusentan have not yet been released, darusentan (and with it most likely the whole 
class of ET-A antagonists) appears unlikely to find its way into our armamentarium 
for the treatment of resistant hypertension[Enseleit et al., 2010].  
 
Conclusion 
As the selective ET-A antagonist darusentan reduced blood pressure by acting 
through a new pharmacological pathway that had not previously been the target of 
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oral antihypertensive drugs, this may permit to achieve blood pressure control in 
patients, who are difficult to treat and who are at increased vascular risk, e. g. 
patients with diabetes mellitus. While, early clinical results from phase II studies 
suggest, that darusentan may find a place in the treatment of resistant hypertension, 
more recent phase III studies could not find a dose-dependent blood pressure 
reduction. Indeed, the DORADO-AC study failed to achieve its co-primary efficacy 
endpoint (changes from baseline to week 14 in trough sitting systolic and diastolic 
blood pressure), and the sponsor of the trial, Gilead Science, announced to terminate 
the further development of darusentan for the treatment of resistant hypertension. 
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Table 1: HEAT-2: Placebo – subtracted mean change from baseline. Results are 
adjusted for baseline and study centre. For systolic and diastolic blood 
pressure, the last value under double – blind treatment was used for each 
individual. The confidence interval was adjusted for baseline blood pressure 
and centre, but not for multiple testing. Modified from Nakov et al[Nakov et 
al., 2002]. 
 
 Systolic blood pressure Diastolic blood pressure 
 Mean [mmHg] 95 % CI [mmHg] p Mean [mmHg] 95 % CI [mmHg] p 
100 mg -11.3 -16.3; -6.2 0.0001 -8.3 -11.1; -5.5 0.0001
30 mg -7.3 -12.3; -2.4 0.004 -4.9 -7.7; -2.2 0.0005








Table 2: Comparison of office blood pressure lowering efficacy of darusentan and 












al., 1998] 500 mg QD A / B 8.4±1.7 5.7±1.0 
Darusentan[Nakov 
et al., 2002] 100 mg QD A 11.3* 8.3* 
Darusentan[Black 
et al., 2007] 300 mg QD A 11.5±3.1 6.3±2.0 
Darusentan[Weber 
et al., 2009] 300 mg QD A 18±19 10±11 
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Figure 2: Changes from baseline in mean 24-h ambulatory blood pressure after 14 
weeks. (A) Change in systolic blood pressure (SBP). (B) Change in diastolic blood 




Page 24 of 24 
